ossificans

os·sif·i·cans

(ŏ-sif'i-kanz)
Ossifying; forming or turning into bone.
[L.]
Medical Dictionary for the Health Professions and Nursing © Farlex 2012

ossificans

(ŏ-sĭf′ĭ-kănz″, kăns″) [L. “bone-making”]
Becoming or forming bony growth.
Medical Dictionary, © 2009 Farlex and Partners
References in periodicals archive ?
Myositis ossificans as a complication of a muscle tendon junction strain of long head of biceps.
Medici and his colleagues transferred the mutated gene that causes Fibrodysplasia Ossificans Progressiva (FOP), into normal endothelial cells.
As shown in cases with fibrodysplasia ossificans progressiva, the disruption of BMP signals can cause HO development (47).
Myositis ossificans is defined as the formation of HO in inflammatory muscle.
Only a few convincing cases of soft tissue ABC have been reported, arising in the superficial soft tissues of the groin, trunk, and within an artery.[7-9] Similar to their bony counterpart, ABC-like changes also have been noted associated with other lesions of soft tissues, such as myositis ossificans or fasciitis.[10]
The disorder, Fibrodysplasia Ossificans Progressiva, can't be operated on as surgery will provoke more abnormal bone growth.
Church members shared our concern and watched our shock and grief when she was diagnosed at the age of four months with a rare, devastating condition called fibrodysplasia ossificans progressiva, or F.O.P.
Clementia Pharmaceuticals announced the early completion of patient enrollment in the MOVE Trial, Clementia's registrational Phase 3 clinical study evaluating the safety and efficacy of palovarotene for the treatment of patients with fibrodysplasia ossificans progressiva.
The common differential diagnosis of melorheostosis includes myositis ossificans, synovial osteochondromatosis, osteoma, parosteal osteosarcoma, focal scleroderma, and Caffey disease.
Biopharmaceutical company La Jolla Pharmaceutical Company (Nasdaq:LJPC) revealed on Tuesday that it has received the US Food and Drug Administration (FDA) Office of Orphan Products Development's orphan drug designation for two novel compounds for fibrodysplasia ossificans progressiva (FOP).
Operative interventions risk further stiffness and myositis ossificans. Continuous traction has the disadvantages of prolonged hospitalisation, resort to frequent radiographic analyses, and inadequate reduction.